Literature DB >> 27407162

Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy.

Natalie A Vandeven1, Paul Nghiem2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27407162      PMCID: PMC4957253          DOI: 10.1200/JOP.2016.014498

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  9 in total

Review 1.  Recent Insights and Advances in the Management of Merkel Cell Carcinoma.

Authors:  Patricia D Banks; Shahneen Sandhu; David E Gyorki; Meredith L Johnston; Danny Rischin
Journal:  J Oncol Pract       Date:  2016-07       Impact factor: 3.840

2.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

3.  UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.

Authors:  Stephen Q Wong; Kelly Waldeck; Ismael A Vergara; Jan Schröder; Jason Madore; James S Wilmott; Andrew J Colebatch; Ricardo De Paoli-Iseppi; Jason Li; Richard Lupat; Timothy Semple; Gisela Mir Arnau; Andrew Fellowes; J Helen Leonard; George Hruby; Graham J Mann; John F Thompson; Carleen Cullinane; Meredith Johnston; Mark Shackleton; Shahneen Sandhu; David D L Bowtell; Ricky W Johnstone; Stephen B Fox; Grant A McArthur; Anthony T Papenfuss; Richard A Scolyer; Anthony J Gill; Rodney J Hicks; Richard W Tothill
Journal:  Cancer Res       Date:  2015-12-01       Impact factor: 12.701

4.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

5.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

7.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Authors:  Paul T Nghiem; Shailender Bhatia; Evan J Lipson; Ragini R Kudchadkar; Natalie J Miller; Lakshmanan Annamalai; Sneha Berry; Elliot K Chartash; Adil Daud; Steven P Fling; Philip A Friedlander; Harriet M Kluger; Holbrook E Kohrt; Lisa Lundgren; Kim Margolin; Alan Mitchell; Thomas Olencki; Drew M Pardoll; Sunil A Reddy; Erica M Shantha; William H Sharfman; Elad Sharon; Lynn R Shemanski; Michi M Shinohara; Joel C Sunshine; Janis M Taube; John A Thompson; Steven M Townson; Jennifer H Yearley; Suzanne L Topalian; Martin A Cheever
Journal:  N Engl J Med       Date:  2016-04-19       Impact factor: 91.245

Review 8.  Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.

Authors:  Natalie Vandeven; Paul Nghiem
Journal:  Immunotherapy       Date:  2016-07       Impact factor: 4.196

9.  Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.

Authors:  Gerald Goh; Trent Walradt; Vladimir Markarov; Astrid Blom; Nadeem Riaz; Ryan Doumani; Krista Stafstrom; Ata Moshiri; Lola Yelistratova; Jonathan Levinsohn; Timothy A Chan; Paul Nghiem; Richard P Lifton; Jaehyuk Choi
Journal:  Oncotarget       Date:  2016-01-19
  9 in total
  5 in total

1.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

Authors:  Vivek Verma; Rajeev K Shrimali; Shamim Ahmad; Winjie Dai; Hua Wang; Sumin Lu; Rahul Nandre; Pankaj Gaur; Jose Lopez; Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Scott A Hammond; Ming Tan; Jingjing Qi; Phillip Wong; Taha Merghoub; Jedd Wolchok; Nir Hacohen; John E Janik; Mikayel Mkrtichyan; Seema Gupta; Samir N Khleif
Journal:  Nat Immunol       Date:  2019-07-29       Impact factor: 25.606

Review 2.  Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

Authors:  Daniela Femia; Natalie Prinzi; Andrea Anichini; Roberta Mortarini; Federico Nichetti; Francesca Corti; Martina Torchio; Giorgia Peverelli; Filippo Pagani; Andrea Maurichi; Ilaria Mattavelli; Massimo Milione; Nice Bedini; Ambra Corti; Maria Di Bartolomeo; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

3.  In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series.

Authors:  Melody J Xu; Susan Wu; Adil I Daud; Siegrid S Yu; Sue S Yom
Journal:  J Immunother Cancer       Date:  2018-05-30       Impact factor: 13.751

4.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.

Authors:  Ann W Silk; Christopher A Barker; Shailender Bhatia; Kathryn B Bollin; Sunandana Chandra; Zeynep Eroglu; Brian R Gastman; Kari L Kendra; Harriet Kluger; Evan J Lipson; Kathleen Madden; David M Miller; Paul Nghiem; Anna C Pavlick; Igor Puzanov; Guilherme Rabinowits; Emily S Ruiz; Vernon K Sondak; Edward A Tavss; Michael T Tetzlaff; Isaac Brownell
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

5.  Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma.

Authors:  Alexandra Aicher; Anca Sindrilaru; Diana Crisan; Wolfgang Thaiss; Jochen Steinacker; Meinrad Beer; Thomas Wiegel; Karin Scharffetter-Kochanek; Ambros J Beer; Vikas Prasad
Journal:  Pharmaceutics       Date:  2022-07-14       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.